Where fat sits matters more than how much of it there is
Two people can weigh the same and face very different risk. The fat that does the damage sits inside and around the organs — the liver and pancreas above all — not in the total-body fraction. A person can be normal-BMI and metabolically ill, or heavier and, for a time, not. So read the depot — the waist, the intra-organ compartment — not a total-adiposity number like BMI or body-fat percentage. And treat the familiar U-shaped “overweight is protective” mortality curve as mostly an artifact of confounding and reverse causation, not a licence.
Three questions follow: what does losing fat actually buy — hard outcomes or only surrogates; what the ectopic-fat ladder drives once safe storage is overwhelmed; and how that one upstream depot loads diabetes, cardiovascular disease, cancer and the knee. One question stays out of scope here: how to take the fat off and keep it off. Diet versus exercise, what happens to muscle, which method moves which outcome, whether the loss lasts — those live in Losing Fat and Keeping It Off.
Where fat sits carries the risk — read the depot, not the scale
The first decision about body fat is not how much but where. Cardiometabolic risk tracks the fat stored in the liver, pancreas and viscera, rather than under the skin, far more faithfully than it tracks total fat mass or the number on the scale. A normal-weight person can be metabolically ill; a heavier person can be, for a time, not. So a total-adiposity reading (BMI, or even body-fat percentage) is the wrong instrument, and the familiar U-shaped “overweight is protective” mortality curve is largely an artifact, not a licence. (Kramer et al., 2013; inferred from Taylor & Holman, 2014)
Three fat compartments are three different objects
Subcutaneous fat is the safe, expandable store; its capacity varies by person and ethnicity and is not itself pathogenic. Intra-organ fat — inside the liver and pancreas — is the pathogenic depot: liver fat drives hepatic insulin resistance, pancreatic fat suppresses insulin secretion. Visceral (intra- abdominal) fat is commonly cast as the villain, but Taylor demotes it to a marker: extent of visceral fat «is a surrogate marker for intra-organ fat ex- cess, but is not pathophysiologically related to adverse metabolic consequences». (Taylor & Holman, 2014) So waist circumference is a surrogate for a surrogate — useful because it tracks the intra-organ fat doing the damage, one step removed from it. (inferred from Taylor & Holman, 2014) -> Ectopic Fat and Depot-Specific Risk
BMI’s protective band is mostly an artifact — adjudicate the arm, not the curve
The observational BMI-mortality curve dips in the overweight range, and that dip is where the “obesity paradox” lives. The 10.6M-participant Global BMI IPD meta-analysis strips it away step by step: the overweight arm (BMI 25-30) walks from an apparent HR 0.96 (0.95-0.97) raw, to 0.99 after adjusting smoking and excluding baseline disease, to 1.03 after dropping the first 5 years of follow-up, to 1.11 (1.10-1.11) once restricted to never-smokers. (Global BMI Mortality Collaboration, 2016) Isolate smoking alone — same disease and follow-up exclusions — and overweight runs 1.07 (1.06-1.07) in never-smokers versus 0.94 (0.94-0.95) in ever-smokers. (Global BMI Mortality Collaboration, 2016) Confounding and reverse causation manufactured the protection; carrying extra weight confers no real benefit -> The U-Shaped Association Artifact.
The genetic check converges. Wade’s Mendelian-randomization analysis in UK Biobank finds the J-shape survives but deflates: it remains «but with a smaller value of BMI at which mortality risk was lowest (~23 vs. ~26 kg/m2 with observational analyses) and apparently flatter over a larger BMI range». (Wade et al., 2018) Read the nadir off the raw observational curve and you overstate the harm of being underweight and understate the harm of being obese — so the low arm is largely artifact, adjudicated by the strong (genetic) check, not merely argued -> BMI and All-Cause Mortality.
Metabolic status beats the BMI band
If risk tracks depot and metabolic state rather than mass, then obesity should not be safe merely because current metabolic markers are clean, and lean people with a bad profile should carry high risk. Kramer’s meta-analysis of observational cohorts shows exactly this: metabolically-healthy obesity is not durably benign (RR 1.24 (1.02-1.55) versus metabolically-healthy normal weight in studies with >=10 years’ follow-up — «there is no healthy pattern of increased weight»), while metabolically-unhealthy normal weight carries RR 3.14 (2.36-3.93). (Kramer et al., 2013)
Opio 2020 refines this on a larger base (23 prospective cohorts, n=4.49M) and answers the sub-question Kramer could not: the excess CVD risk holds even with zero metabolic risk factors — metabolically- healthy overweight RR 1.51 (1.21-1.88), metabolically-healthy obesity RR 2.18 (1.28-3.71) — and does not require a decade of latency (present at both <10y and >=10y, subgroup-difference p=0.98). Metabolically-unhealthy normal weight again dominates at RR 3.07 (2.27-4.15). (Opio et al., 2020) The honest bound: these are observational RRs with high heterogeneity and live fitness confounding, and the absolute excess is modest — the only held absolute anchor is Kramer’s ~0.7% over 10-11 years — so metabolically-healthy obesity licenses continued, not urgent, attention -> Baseline Risk and the Relative-Absolute Split.
On a hard endpoint, abdominal fat is the harmful depot — but the marker you pick barely changes the prediction
Kramer and Opio are metabolic-status sources; INTERHEART extends the depot distinction to a hard endpoint (first acute MI, 27,098 people, 52 countries) and reads the same shape. Adjusted for BMI, the top-versus-bottom-quintile odds ratio for MI is 1.77 (1.59-1.97) for waist (harmful) and 0.73 (0.66-0.80) for hip (protective); waist-to-hip ratio is the strongest single marker at 1.37 (1.34-1.41) per SD, while BMI is the weakest at 1.10 (1.07-1.13) and its whole MI association vanishes after adjusting for WHR (1.44 -> 1.12) then the other risk factors (-> 0.98). (Yusuf et al., 2005) A bigger waist is harmful — the depot claim, now on a cardiovascular event rather than a glycemic one. The protective hip arm is weaker evidence: INTERHEART measured hip circumference, not hip fat, and its authors note that «increasing hip measurements might also indicate increased gluteal muscle and could be a marker of overall skeletal muscle mass» (Yusuf et al., 2005); it is also the arm most exposed to the case-control artifact described below.
INTERHEART read this as proof that clinics should abandon BMI and switch to waist-to-hip ratio. A larger prospective test overturns that marker-ranking claim while leaving the depot claim intact. ERFC 2011 pooled 58 cohorts (221,934 people) with BMI, waist and WHR measured in the same people at baseline, and found the three near-identical in strength — per-SD hazard ratios for cardiovascular disease of 1.23 (1.17-1.29) for BMI, 1.27 (1.20-1.33) for waist and 1.25 (1.19-1.31) for WHR — and «reliably refute[s] previous recommendations to adopt baseline waist-to-hip ratio instead of BMI as the principal clinical measure of adiposity» (Collaboration, 2011).
The ~3-fold WHR-over-BMI gap is a case-control artifact: acute illness before an MI strips skeletal muscle, lowering hip circumference and raising WHR in the cases measured after the event. BMI is also the more reproducible measure (regression-dilution ratio 0.95 vs 0.63 for WHR).
Two things survive the contest, and both bear on the decision. First, abdominal adiposity is still a real, modifiable determinant — ERFC is explicit that its null concerns prediction on top of the intermediates, not aetiology: once a person’s blood pressure, lipids and glucose are known, «simple adiposity measures provide little or no additional information on cardiovascular risk», because the fat acts through those markers.
Second, ERFC’s sample was 90% European descent, so INTERHEART’s finding that BMI carries no MI signal at all in South Asian, Arab and mixed-race African groups is untested, not refuted. Net: for a developed-country adult whose risk factors are known, BMI is an adequate and more-reproducible clinical measure, and the case for switching to WHR does not survive prospective design. The WHR case is strongest where lipids are unmeasured and in the non-European strata ERFC could not test. (Collaboration, 2011; inferred from Yusuf et al., 2005) -> Waist-to-Hip Ratio and Cardiovascular Risk, BMI vs Abdominal-Adiposity Markers - Which Predicts CVD.
Central fat predicts death independent of BMI — and its curve barely dips
The all-cause-mortality endpoint gives the depot claim its sharpest form. Jayedi pooled 72 cohorts in a dose-response meta-analysis (2.5M people, 150,164 deaths): waist circumference carries excess death at HR 1.11 per 10 cm (1.08-1.13) and waist-to-hip ratio at 1.20 per 0.1 unit (1.15-1.25), and «Positive associations persisted after accounting for body mass index» — for waist the association does not merely survive BMI adjustment but strengthens, to 1.17 (1.13-1.22) in the studies that adjusted for it. So two people at the same BMI carry different mortality risk according to where the fat sits, and the waist reading carries information the scale number does not. Hip and thigh run the other way (hip 0.90 per 10 cm, thigh 0.82 per 5 cm) — the same waist-harmful, hip-protective split INTERHEART read on the heart, now on death. (Jayedi et al., 2020)
The shape of that curve sharpens the artifact reading above. Where the BMI curve carries a substantial protective-looking lower arm — the obesity paradox — the central-fat curves barely dip: waist-to-hip ratio is monotone, «Overall the relations were monotonic with little evidence of sharp changes at particular cut-off points». The frailty and low-lean-mass confound that manufactures BMI’s paradox does not load the low-waist end -> The U-Shaped Association Artifact. (Jayedi et al., 2020)
Jayedi lands a third position on the which-marker debate, distinct from INTERHEART’s switch to WHR and ERFC’s BMI is adequate: «measures of central adiposity could be used as a supplementary approach, in combination with body mass index, to determine the risk of premature death». Two bounds hold it honest — heterogeneity is high (I2 85-97%), and the waist signal fades to non-significance past age 60 -> Central Adiposity and All-Cause Mortality. (Jayedi et al., 2020)
Is visceral fat the pathogenic depot, or a marker for intra-organ fat? — a ladder, not a contradiction
Two readings sit side by side. INTERHEART and AASLD put central adiposity at the causal centre: INTERHEART calls waist and WHR «simple and crude surrogate measures for visceral obesity, which is probably the key determinant of metabolic abnormalities» (Yusuf et al., 2005), and AASLD states that «Visceral fat, which is more metabolically active and inflammatory than subcutaneous fat, mediates the majority of this risk.» (Rinella et al., 2023) Taylor goes one step past both, demoting visceral fat to a marker of the intra-organ (hepatic and pancreatic) excess that actually does the damage.
This is not a contradiction to adjudicate but a nested causal ladder — waist marks visceral fat marks ectopic fat — where the sources stop at different rungs. The issue is not fully joined: AASLD’s own mechanism routes visceral fat’s harm through intra-organ fat («insulin signaling is progressively impaired, promoting the inappropriate release of fatty acids leading to intrahepatic lipid accumulation») (Rinella et al., 2023) — compatible with Taylor’s marker reading if the two depots are tightly coupled.
Little hangs on it: every rung points to the same lever (an energy deficit) and the same measurement — waist stays the right thing to read precisely as a marker, one step removed from the fat doing the damage. (Rinella et al., 2023; inferred from Taylor & Holman, 2014; Yusuf et al., 2005)
Body-fat percentage is better than BMI but still the wrong target — and its optimum is a named gap
Body-fat percentage measures the same thing BMI does — total adiposity — more accurately, but it is the same category of measurement, and sits subordinate to depot in this hierarchy. Where the fat sits carries the risk, not the total-fat fraction. No held gold source carries a body-fat-percentage optimum or nadir against all-cause mortality; asserting one would launder a total-adiposity number into the depot claim it cannot make. The BF%-versus-mortality threshold is an explicit named gap — its absence, not a number. Read depot (waist/WHR); treat any total-adiposity cutpoint, BMI or BF% alike, as a coarse screen, not a target. (inferred from Taylor & Holman, 2014; Yusuf et al., 2005)
The Personal Fat Threshold — and why reversal happens below BMI 25
Taylor’s model gives the individual-versus-population gap a name, the personal fat threshold (PFT), defined at the organ level: «It is hypothesized that each individual has a PFT (dotted line) above which excess fat is stored within the liver and the pancreas.» — and «the hypothesized PFT is independent of BMI». (Taylor & Holman, 2014) The data bear the reframe out — 36% of newly-diagnosed T2DM occurred at BMI <25 (against 64% below 25 in the contemporaneous UK population), so diabetes does not require obesity, only carrying more fat than you can store safely. The threshold itself shifts by ethnicity (BMI 30 in a Caucasian is matched at 25.2 in South Asians, 27 in African/Caribbeans). (Taylor & Holman, 2014)
The reversal arm is the sharpest decision-change here: a normal-weight person with T2D is above their PFT even at BMI <25, and responds to weight loss — at a smaller required loss. In Taylor’s cohort, at a presenting glucose of 8-10 mmol/l, «normoglycaemia was achieved with a mean weight loss of 13% if body weight was normal, whereas a mean weight loss of 21% of body weight was required to achieve this in the whole cohort». (Taylor & Holman, 2014) This is the stratum the remission trials routinely exclude (DiRECT required BMI >=27), yet the depot lens says to offer them the lever -> Total Diet Replacement and Type 2 Diabetes Remission.
Menopause is where read-the-waist bites hardest
Menopause turns the depot-over-scale rule from advice into a specific instruction for a large stratum. The largest meta-analysis of midlife body composition splits two things that get conflated: the amount of fat a woman gains across the transition tracks aging, not menopause — no menopause-by-age interaction shows up on any total-fat measure. Menopause more likely adds — on the source’s own hedged reading (mostly cross-sectional, framed as possible rather than established) — a central redistribution: trunk and visceral fat up, leg fat down, tracking the rising testosterone-to-estradiol ratio. (Ambikairajah et al., 2019)
That sharpens the measurement rule. In this older group, BMI is confounded not only by depot but by the aging changes of bone loss, sarcopenia and height shrinkage — each moves BMI without tracking fat — so a normal BMI does not clear a post-menopausal woman of central-adiposity risk: read the waist. The lever is the one already ranked — menopause raises the central-fat baseline, so the same visceral-fat drawdown buys more absolute benefit (route (a): a shifted baseline, not a new subgroup effect) -> Menopause and the Shifting Levers, Baseline Risk and the Relative-Absolute Split. (inferred from Ambikairajah et al., 2019)
The decision
Rank cardiometabolic risk by central adiposity (waist, waist-to-hip ratio) and metabolic status, not by BMI and not by a body-fat percentage. Where the full metabolic panel is already in hand, it dominates the anthropometric marker — waist and WHR earn their keep mainly as a screen when blood pressure, lipids and glucose are not yet known, and as a reason to look harder (Collaboration, 2011). A normal-BMI person with a high WHR carries elevated MI risk, and a high WHR or a bad metabolic panel is consistent with fat stored in the organs, though no tape measure can show where their personal threshold sits; a currently-clean panel in an obese person buys less durable safety than it appears to.
The lever in every case is negative energy balance, whatever delivers it, drawing the intra-organ and visceral depots back down — the arithmetic of who benefits how much then runs through baseline risk -> Baseline Risk and the Relative-Absolute Split. (Kramer et al., 2013; inferred from Taylor & Holman, 2014; Yusuf et al., 2005)
Losing fat reliably moves the markers; it moves hard outcomes only by some routes
The intuitive claim is that shedding fat prevents heart attacks and extends life. Tested head-on, the claim splits: fat loss moves surrogates — weight, HbA1c, blood pressure, lipids, inflammation, liver enzymes — almost every time, but it moves hard outcomes (major cardiovascular events, mortality) only by particular routes and in particular people. The demonstrated hard-outcome wins are narrow: bariatric surgery and a GLP-1 drug. Lifestyle weight loss has not cleanly shown one. Most of the “weight loss works” evidence lives on the surrogate side of that line, and reading it as an outcome win is the error this section guards against. (inferred from Look AHEAD Research Group, 2013; Ma et al., 2017)
The landmark null: every surrogate moved, the events did not
Look AHEAD is the largest, longest randomized test of the lifestyle route — 5,145 overweight adults with type 2 diabetes, intensive lifestyle intervention versus diabetes education. The intervention improved fitness and every cardiovascular risk factor except LDL cholesterol (Look AHEAD Research Group, 2013); a Look AHEAD CRP substudy separately found the lifestyle arm drove a ~40% relative reduction in C-reactive protein, similar in statin and non-statin users (Belalcazar et al., 2013).
Yet the primary cardiovascular composite was null: HR 0.95 (95% CI 0.83-1.09, P=0.505), and the trial was stopped for futility at 9.6 years median follow-up. (Look AHEAD Research Group, 2013) A bundle of favourable surrogate changes bought no measurable reduction in events — the Surrogate Outcomes warning made concrete. (inferred from Look AHEAD Research Group, 2013)
The null is narrower than it sounds. The two arms converged over follow-up, so the sustained contrast was a modest weight-loss dose rather than big-loss-versus-none. Both arms received good diabetes care, shrinking any between-arm gap. And the trial was sized to detect only a large effect, leaving a smaller true benefit undetectable. (inferred from Look AHEAD Research Group, 2013)
The meta-analysis generalizes it: CV events null, all-cause mortality falls by a non-cardiac route
Ma 2017 pools 54 RCTs (30,206 mostly non-diabetic obese adults, weight-reducing diets) and splits cleanly. On the heart it confirms Look AHEAD: CV events RR 0.93 (95% CI 0.83-1.04) and CV mortality RR 0.93 (0.67-1.31), both null. But all-cause mortality falls: RR 0.82 (0.71-0.95), high quality, ~6 fewer deaths per 1000. (Ma et al., 2017) Since CV events are null, that mortality benefit is not routed through the heart — a puzzle the CV endpoint cannot resolve.
Two honesty notes bound this. Look AHEAD carried 54.6% of the CV-strand weighting, so “the MA generalizes Look AHEAD” is partly self-containing there; but the all-cause benefit is not a Look AHEAD artefact — without that trial it is larger (RR 0.78, 0.63-0.96, I^2 = 0%). And the trials were “usually low in fat and saturated fat,” so part of the benefit may travel the SFA -> LDL channel rather than weight loss per se — the design cannot separate the two. (Ma et al., 2017)
Where hard outcomes DO fall: the extreme surgical dose and the drug route
Bariatric surgery in severe obesity (SOS) sits at the opposite end of the dose-response and finds the mortality benefit the moderate-dose trials could not. It reports an unadjusted all-cause-mortality HR 0.76 (95% CI 0.59-0.99, P=0.04), strengthening to an adjusted HR 0.71 (P=0.01) because the surgery arm carried baseline survival disadvantages (heavier, more smokers). The design firewall is essential: SOS is not an RCT — patients self-selected (“desiring surgery”), so unmeasured motivational confounding is untouched by adjustment. (Sjöström et al., 2007) SOS also cannot attribute the benefit to weight loss per se (surgery alters gut hormones and satiety), and mortality did not track the degree of weight loss within the study — so it anchors a large-intervention point, not cleanly a large-weight-loss-dose one.
The drug route supplies the clean randomized hard-outcome win in obesity itself: in secondary-prevention obesity, semaglutide cut the CV composite (MACE HR 0.80, 95% CI 0.72-0.90). Full benefit-risk appraisal, per-agent ranking, and dosing live in the separate GLP-1 deliverable -> Semaglutide for Cardiovascular Risk in Obesity, GLP-1 Drugs; here it functions only as the demonstrated drug-route data point.
That win is not a one-off. A class meta-analysis of 11 cardiovascular-outcome trials (Badve 2024; 85,373 participants) finds the whole GLP-1 receptor-agonist class cuts hard events — «a 13% reduction in the risk of MACE (HR 0·87, 95% CI 0·81 to 0·93; high-certainty evidence)» in the type-2-diabetes trials, and effects «appeared consistent regardless of diabetes status» (Badve et al., 2025). Only nonfatal heart attack differed by diabetes status (p-heterogeneity 0.02, both groups still benefiting), and SELECT is the only trial without diabetes (Badve et al., 2025).
That sharpens the route-matters point rather than crediting weight loss: most of the pooled trials were glucose-lowering type 2 diabetes trials with modest weight change. Badve does not report when the curves separate. In the single trial SELECT (obesity without diabetes, established CVD) the benefit «occurred early after the initiation of treatment», and its authors suggest that physiological changes «beyond the magnitude of body-weight loss may have mediated at least part of the cardiovascular benefit», while calling the mechanisms speculative (Lincoff et al., 2023). That points to a drug-specific effect, not purely a weight-loss effect. So the drug route to CV events is robust and class-wide, while the lifestyle weight-loss route’s CV-event null still stands -> GLP-1 Receptor Agonists and Cardiovascular and Kidney Outcomes. (inferred from Badve et al., 2025)
Tirzepatide reaches surgical-scale loss (SURMOUNT-OSA: body-weight treatment difference -16.1%, 95% CI -18.0 to -14.2) and moves the CV risk markers (systolic BP -7.6 mm Hg, -10.5 to -4.8; hsCRP down) plus the OSA-severity surrogates — but it is surrogate-only, with no powered CV endpoint, no deaths, and a 52-week horizon. Do not borrow SELECT’s benefit for it; its hard-outcome evidence AWAITS SURMOUNT-MMO. (Malhotra et al., 2024)
The lifestyle hard-outcome null in low-risk people — DPPOS over 21 years
The sharpest bound on the lifestyle route comes from diabetes prevention followed long enough to adjudicate events. DPPOS followed the three DPP arms a median 21 years and was null on the cardiovascular endpoint: metformin MACE HR 1.03 (95% CI 0.78-1.37) and lifestyle MACE HR 1.14 (0.87-1.50) versus placebo — point estimates trending the wrong way for lifestyle. (Goldberg et al., 2022) This is a bounded null, not a demonstration of no effect: the cohort became low-risk and heavily treated (statins 56-62%, antihypertensives 68-74%), leaving little absolute CV risk to remove. Note that preventing diabetes incidence — a disease-onset outcome one rung above a pure surrogate — was never in doubt in DPP; what DPPOS shows is that the incidence win did not carry to hard CV events in this stratum.
The tension resolved: route, baseline risk, and evidence grade — not a contradiction
The positive results (SOS all-cause HR 0.71; Ma all-cause RR 0.82) and the nulls (Look AHEAD HR 0.95; DPPOS MACE HRs crossing 1) are not a contradiction about whether weight loss “works.” Set against a parameter table they are different quantities:
| Axis | Positive results | Null results |
|---|---|---|
| Route | surgery (SOS), GLP-1 drug (SELECT) | lifestyle (Look AHEAD, DPPOS) |
| Baseline risk | severe obesity / higher-risk cohorts | lower-risk, well-treated (statins, BP drugs) |
| Endpoint / grade | all-cause mortality; observational (SOS) or RCT (SELECT) | CV-events composite; RCT |
The clinching evidence is baseline risk. The same diabetes-prevention question, asked in a higher-risk cohort (Da Qing, 30-year follow-up), did show a lifestyle CV benefit: MACE HR 0.74 (95% CI 0.59-0.92). (Goldberg et al., 2022) Absolute benefit scales with baseline risk (route (a) — no subgroup claim needed; Baseline Risk and the Relative-Absolute Split), so a low-risk cohort has little absolute risk to remove and even a real relative effect is hard to detect. The honest composite: hard-outcome benefit is demonstrated for surgery and a GLP-1 drug, plausible-but-unproven for lifestyle in a low-risk stratum, and scaling with baseline risk. (inferred from Goldberg et al., 2022; Ma et al., 2017; Sjöström et al., 2007)
One more contrast: an energy-unrestricted Mediterranean pattern (PREDIMED), with little weight change, cut CV events HR 0.70 (95% CI 0.55-0.89) in high-risk primary prevention. So what you eat appears to carry a CV-event signal that how much you weigh did not — populations and comparators differ, so this is a reasoned contrast, not a head-to-head. (Estruch et al., 2018)
Surrogates that predict but are not targets
Even a strong predictor of events is not automatically a lever. The triglyceride-glucose (TyG) index, a cheap insulin-resistance proxy, predicts incidence — CAD HR 2.01 (95% CI 1.68-2.40) — yet is null on mortality: CV mortality 1.10 (0.82-1.47) and all-cause 1.08 (0.92-1.27), both CIs crossing 1. A predictor’s signal is outcome-specific, and TyG is silent on the outcomes people weight most; it flags the stratum, it does not name the lever. (Liu et al., 2022) The counter-case is LDL/apoB, a surrogate whose causal transmission to ASCVD is evidenced, so lowering it does reduce events — not all surrogates are equal -> Surrogate Outcomes.
Decision relevance
- Pursue fat loss for the outcomes it demonstrably moves. Its priority never rested on a proven hard-CV-event reduction: it rests on diabetes remission and prevention, glycaemic control, MASLD regression, and function -> Fatty Liver MASLD and Weight Loss, Lifestyle vs Metformin for Diabetes Prevention. The Look AHEAD null refines the claim rather than undermining it.
- Do not oversell a heart-attack reduction the largest lifestyle trial failed to show. For a low-risk person pursuing lifestyle weight loss, “this will lower your risk of a heart attack” is weakly evidenced; the demonstrated CV levers in that stratum are the direct ones (statin, BP control).
- A widely-cited >=10%-responder CV signal exists but is not held as a magnitude. A Look AHEAD post-hoc analysis (Gregg 2016) is reported — via SELECT’s and DiRECT’s discussions — to show a ~21% cardiovascular-event reduction in those losing >=10%, but the primary paper is not held; it is an awaited figure, not a fact this cut can assert. (Lean et al., 2018)
- Where hard outcomes are the concern, route and baseline risk size the choice. A mature GLP-1 drug with a demonstrated MACE benefit, or a high enough baseline risk, is where the hard-CV rock is largest (Baseline Risk and the Relative-Absolute Split).
The pathogenic fat is inside the organs — draw it down and the liver ladder reverses in dose
The excess fat does its damage according to where it sits, and the most dangerous place is inside the liver and pancreas. Taylor’s model puts intra-organ fat at the centre: liver fat is «pivotal» to hepatic insulin resistance, and he demotes the more-famous visceral depot to a readout — «Extent of visceral fat accumulation is a surrogate marker for intra-organ fat excess, but is not pathophysiologically related to adverse metabolic consequences». (Taylor & Holman, 2014) Fatty liver (MASLD, renamed from NAFLD in 2023) is the clinically visible edge of that intra-organ depot, so its weight-loss lever is the same depot-drawdown the cardiometabolic pages already rank first -> Ectopic Fat and Depot-Specific Risk.
How much does that pivotal depot track with downstream disease? In Mantovani’s meta-analysis of 16 cohort studies (214,805 people, 10,356 new diabetes cases), people with fatty liver had a pooled HR 2.22 (1.84-2.60) for incident diabetes, holding at 1.85 (1.47-2.22) across the 10 studies with full confounder adjustment (Mantovani et al., 2018). This is observational, so read it as a risk association, not proof the liver fat causes the diabetes.
The association is severity-graded: it rises across ultrasound steatosis scores (HR 2.15, 1.72-2.58, I2=0%) and reaches HR 2.63 (1.57-3.70) in more severe NAFLD (Mantovani et al., 2018). The headline pool is heterogeneous while the steatosis-score gradient is not, so the dose-response is the sturdier signal, though it rests on only three studies. The case for acting comes from the interventional reversal below, not these cohorts: drawing the depot down reverses the liver ladder in dose, which is why it ranks as a first-order lever.
Sustained weight loss reverses each rung of liver disease by dose — a dose-response histology ladder. EASL states «a bodyweight reduction of >=5% is required to reduce liver lipid content, 7-10% to improve inflammation, and >=10% to improve fibrosis», with «a dose-dependent association between the amount of weight loss and the extent of improvement in biomarkers of liver damage». (European Association for the Study of the Liver, 2024) A second national body, AASLD, draws the same-shaped curve — «Weight loss of 3%-5% improves steatosis, but greater weight loss (>10%) is generally required to improve NASH and fibrosis» — differing only in where the middle rung sits. (Rinella et al., 2023)
| Rung (histological outcome) | EASL 2024 (GRADEd) | AASLD 2023 (un-GRADEd) |
|---|---|---|
| Steatosis (liver fat) | sustained >=5% | 3-5% |
| Steatohepatitis (NASH) | 7-10% | folded into >10% |
| Fibrosis | >=10% | >10% |
These are guideline rungs, not interval-bearing effect estimates: EASL traces the ladder to a single histology-endpoint RCT (Vilar-Gomez 2015), so read the numbers as name-the-curve thresholds whose studied support is one trial, not a pooled dose with confidence intervals. (European Association for the Study of the Liver, 2024)
Three caveats bound the lever, all from EASL: «a limited proportion of individuals achieve a weight reduction of >=5%»; loss peaks at 6 months then regains to «about 5% at 12-24 months» with partial liver-fat regain; and «evidence for an effect of weight reduction by lifestyle modification on advanced fibrosis or cirrhosis is insufficient» — the lever works on the reversible stages, not once bridging fibrosis or cirrhosis is established. (European Association for the Study of the Liver, 2024)
Composition moves liver fat beyond calories — but it is the fat type, not the carbohydrate fraction
Once a person is losing weight, what they eat at a given calorie level is a second-order lever on liver fat. The fabric can separate the real composition signal from popular belief because a gold SR-MA pooled only isocaloric RCTs (26 trials, 32 comparisons), holding energy equal between arms. Its effects are standardized mean differences (SMD; 0.2 small, 0.5 medium, 0.8 large — negative = liver fat fell), never percentages of liver fat removed. (Winters-van Eekelen et al., 2020)
| Swap (isocaloric) | SMD (95% CI); n comparisons | Read |
|---|---|---|
| Unsaturated vs saturated fat | -0.80 (-1.09 to -0.51); 4 | large reduction (unsaturated favoured) |
| Carbohydrate -> protein | -0.33 (-0.54 to -0.12); 5 | moderate reduction (protein favoured) |
| Total fat <-> carbohydrate | 0.01 (-0.36 to 0.37); 12 | null — the fat/carb ratio is not the lever |
(Winters-van Eekelen et al., 2020)
The evidence does not support the claim that fructose and carbohydrates uniquely drive liver fat, but it cannot rule it out. At equal calories the carbohydrate story finds no support: the total-fat<->carbohydrate swap is null (SMD 0.01), and a separate gold SR-MA found only one trial that swapped fructose for glucose at equal energy and measured liver fat (2 weeks, 32 centrally overweight men). Neither diet changed liver fat (+0.11% ± 2.1%), and the two «did not differ in any hepatic outcome measure» (Chung et al., 2014). That isocaloric comparison rests on a single study, so it is insufficient evidence for a fructose-specific effect, not proof of none.
The liver-fat rise Chung found sits in the added-energy arm — hypercaloric fructose raised intra-hepatic lipid 54% (95% CI 29-79%) vs weight maintenance, but at equal excess energy fructose ~= glucose, so the effect «appear[s] to be confounded by excessive energy intake». (Chung et al., 2014)
What the evidence does support is not a special carbohydrate mechanism, which stays unproven either way, but two composition moves — replacing saturated with unsaturated fat (large SMD) and cutting excess liquid energy: sugar-sweetened soda is the one dietary factor Peng’s umbrella graded HIGH, RR 1.53 (1.34-1.75), where «the quality of evidence was only high for the association of sugar-sweetened soda with increased NAFLD risk». (Peng et al., 2022)
Caveat — the ceiling on all three arms is that they move a surrogate. Every effect above is on liver-fat content, and AASLD flags that even histology is «two surrogate steps» from the endpoints that matter: «Additional studies are needed to better understand the long-term association among changes in liver fat, histological response, and clinical outcomes.» (Rinella et al., 2023)
The risk MASLD carries is mostly extrahepatic — it feeds diabetes and cardiovascular disease
For most people with fatty liver, the danger is not the liver. EASL is explicit that «the presence of steatosis in the general population is not associated with a clinically meaningful increase in the risk of liver-related outcomes» — liver risk tracks fibrosis stage, not fat. (European Association for the Study of the Liver, 2024) The load sits downstream: MASLD carries «higher risk of non-fatal cardiovascular disease (HR 1.40)», coronary heart disease (OR 1.33), heart failure (OR 1.5), chronic kidney disease, and «a more than two-fold increased risk of an incident diagnosis of T2D». (European Association for the Study of the Liver, 2024)
Two honesty notes bind these figures. First, EASL reports them as bare point estimates — the guideline text carries no confidence intervals for the HR 1.40, OR 1.33, or OR 1.5, so they enter as guideline-cited associations, not interval-bearing effects. Second, the causal direction is unresolved — a named [G] gap. The >2x incident-T2D and HR 1.40 figures are observational associations. No held Mendelian-randomization umbrella settles whether fatty liver drives T2D or the two share an upstream cause (insulin resistance), so the direction NAFLD/MASLD <-> T2D is a hole in the evidence, not a resolved arrow. (inferred from European Association for the Study of the Liver, 2024)
So for the metabolic-syndrome stratum MASLD adds no separate intervention — it adds a reason and a target (>=7-10% loss for the inflammatory stage) to the weight loss already indicated for cardiometabolic risk. Only one lever here reaches a patient-important endpoint — bariatric surgery, the aggressive form of the same weight-loss lever: «Resolution of NASH without worsening of fibrosis occurred in 80% of patients 1 year following bariatric surgery, which was maintained at 5 years». (Rinella et al., 2023) Full drug/surgery benefit-risk appraisal lives in GLP-1 Drugs; here the point is that the mortality signal, where it exists, tracks large sustained loss, not a distinct mechanism.
Downstream disease — the same fat drives cancer and loads the knee
Cancer: broadly graded, but the wiki holds no per-person magnitude. WCRF grades greater body fatness a convincing or probable cause of many cancers and puts it first because the evidence is «particularly strong … and has grown stronger over the last decade»; «12 of the 17 cancers reviewed by the CUP are linked to greater body fatness», and IARC independently adds thyroid cancer, multiple myeloma and meningioma. (World Cancer Research Fund & American Institute for Cancer Research, 2018)
Carry this as a graded qualifier, not a number: WCRF does not quantify a per-person effect, so there is no CI-bearing body-fatness -> cancer risk estimate to state — the honest form is convincing/probable across 12-of-17 sites, an absence of magnitude, not a hazard ratio. Two edges: risk rises «even within the so-called ‘healthy’ range» (graded, not a BMI-25 threshold), and body fatness in young adulthood runs opposite — a probable-graded protective arm with «no stated mechanism» that the wiki treats as a candidate artifact until it survives a genetic or referent check, not a sign-flip -> The U-Shaped Association Artifact. (World Cancer Research Fund & American Institute for Cancer Research, 2018)
Knee osteoarthritis: here the fabric does hold CI-bearing function outcomes. The IDEA RCT (454 overweight/obese adults, K-L 2-3 knee OA, 18 months) showed diet-plus-exercise beat exercise alone on pain — «the D + E group had less pain relative to the E (mean score, 1.02; 95% CI, 0.33-1.71; P = .004) and D (1.13; 95% CI, 0.44-1.82; P = .001) groups» — with 38% of D+E reporting little or no pain versus ~20% in either single arm, and a monotone dose-response favouring >=10% loss over the studied 0-32% range. (Messier et al., 2013)
Exercise adds function safely: the EULAR SR-MA found «moderate effects … of aerobic exercises and resistance training on cardiovascular fitness (SMD 0.56 (95% CI 0.38 to 0.75)) and muscle strength (SMD 0.54 (95% CI 0.35 to 0.72))», with no effect on flexibility (SMD 0.12, 95% CI -0.16 to 0.41 — insufficient evidence, not a proven null). (Rausch Osthoff et al., 2018) On the incidence side the same lever dominates: per BMI unit, adjusted OR 1.17 (1.10-1.24) for radiographic knee OA, with overweight/obesity plus prior injury (aOR 2.67, 1.41-5.05) accounting for 14% of cases — adiposity is the top modifiable rock (77% of that attributable fraction), so the same depot-drawdown that serves the liver and heart also unloads the joint. (Duong et al., 2025) -> Knee Osteoarthritis Incidence and Risk Factors
The synthesis for U3. One depot — intra-organ and central fat — sits upstream of a liver ladder, a diabetes risk, a cardiovascular load, a cancer footprint and a mechanically-loaded knee, and one sustained weight-loss lever draws it down across all of them. That shared upstream is a structural-leverage point: for the overweight metabolic patient the same loss buys liver, cardiometabolic, cancer-risk and joint benefit at once — which is why depot-drawdown, not any single-disease diet, is the move.
The decision: read the depot, target it, and know what losing it buys
Put together, the state of a person’s body fat settles three things and hands off a fourth. Where the fat sits governs the risk — the intra-organ and visceral depot, read through the waist and the metabolic markers, not the BMI band or the scale number, and the U-shaped “overweight is protective” curve is mostly an artifact to correct, not a licence -> The U-Shaped Association Artifact. Losing that fat reaches hard outcomes by specific routes, not universally — the surrogate markers move almost every time, but events fall where the dose is large (bariatric surgery), where the method carries its own outcome win (a GLP-1 drug), or in the metabolic-syndrome cluster where remission is the endpoint. In otherwise low-risk people the lifestyle-loss hard-outcome signal is thin -> Surrogate Outcomes. The pathogenic fat is inside the organs, and drawing it down reverses the liver ladder and unloads the cardiometabolic, cancer and joint burden it feeds. So the thing to target is the depot, not the scale.
What this deliverable deliberately does not decide is how to take the fat off and keep it off. Three questions live in Losing Fat and Keeping It Off instead: the method comparison (diet versus exercise, total diet replacement, carbohydrate restriction, a GLP-1 drug), what else is lost with the fat (lean mass, function), and the durability problem (most people regain, and the body defends the higher weight). The distinct question of preventing or reversing type 2 diabetes as a disease — not the fat-level question this page answers — lives in Type 2 Diabetes.
This wiki grades coherence and source-fidelity, not realized outcomes: no operation here closes the loop from a recommendation to what actually happened to a person who followed it. Read the confidence and the named gaps as bounds on the evidence, not a guarantee about your case.
Evidence box
Question ’For an adult across the body-fat range: does where fat is stored change its effect on patient-important outcomes more than how much there is, is a given person”s fat actually raising their risk, and does losing it reach hard outcomes rather than only surrogates — so that the depot, not the scale number, is the thing to read and to target? (How to lose fat and keep it off is a separate decision -> Losing Fat and Keeping It Off.)’ Evidence included 30 sources — 15 gold, 14 high, 1 moderate Overall certainty Medium (see Rating Certainty of Evidence) Source-selection note 1 source(s) below the gold/high evidence bar feed this page: Taylor (mechanism, moderate). Their roles and limitations are described in the text. Last updated 2026-10-07 · Independently reviewed: No · Full edit history